ES2422657A1 - Composición farmacéutica sólida de cilostazol - Google Patents
Composición farmacéutica sólida de cilostazolInfo
- Publication number
- ES2422657A1 ES2422657A1 ES201230213A ES201230213A ES2422657A1 ES 2422657 A1 ES2422657 A1 ES 2422657A1 ES 201230213 A ES201230213 A ES 201230213A ES 201230213 A ES201230213 A ES 201230213A ES 2422657 A1 ES2422657 A1 ES 2422657A1
- Authority
- ES
- Spain
- Prior art keywords
- cilostazol
- relates
- composition
- solid
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición farmacéutica sólida de cilostazol. - La presente invención se refiere a una composición farmacéutica sólida de cilostazol que comprende cilostazol como principio activo, un agente aglutinante que contiene una mezcla de un alcohol de azúcar y talco, y, opcionalmente, un agente disgregante. Dicha combinación de excipientes confiere una solubilidad apropiada al principio activo. También se refiere al uso de dicha composición para la preparación de formas farmacéuticas de cilostazol para su administración por vía oral. La invención se refiere también a comprimidos preparados con la composición de la invención, que presentan unas propiedades apropiadas en cuanto a la solubilidad y a la biodisponibilidad del cilostazol. También se refiere a procedimientos para preparar la composición y comprimidos de cilostazol, así como a su uso como medicamentos.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230213A ES2422657B1 (es) | 2012-02-10 | 2012-02-10 | Composición farmacéutica sólida de cilostazol |
PCT/ES2013/070072 WO2013117793A1 (es) | 2012-02-10 | 2013-02-08 | Composición farmacéutica sólida de cilostazol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201230213A ES2422657B1 (es) | 2012-02-10 | 2012-02-10 | Composición farmacéutica sólida de cilostazol |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2422657A1 true ES2422657A1 (es) | 2013-09-12 |
ES2422657B1 ES2422657B1 (es) | 2014-06-11 |
Family
ID=48946935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201230213A Active ES2422657B1 (es) | 2012-02-10 | 2012-02-10 | Composición farmacéutica sólida de cilostazol |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2422657B1 (es) |
WO (1) | WO2013117793A1 (es) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020058066A1 (en) * | 2000-09-22 | 2002-05-16 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol dry coated tablet |
US7144585B1 (en) * | 1999-03-25 | 2006-12-05 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol preparation |
WO2009107864A2 (en) * | 2008-02-29 | 2009-09-03 | Otsuka Pharmaceutical Co., Ltd. | An orally disintegrating tablet |
-
2012
- 2012-02-10 ES ES201230213A patent/ES2422657B1/es active Active
-
2013
- 2013-02-08 WO PCT/ES2013/070072 patent/WO2013117793A1/es active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7144585B1 (en) * | 1999-03-25 | 2006-12-05 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol preparation |
US20020058066A1 (en) * | 2000-09-22 | 2002-05-16 | Otsuka Pharmaceutical Co., Ltd. | Cilostazol dry coated tablet |
WO2009107864A2 (en) * | 2008-02-29 | 2009-09-03 | Otsuka Pharmaceutical Co., Ltd. | An orally disintegrating tablet |
Non-Patent Citations (1)
Title |
---|
JINNO, JUN-ICHI, et al; In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol; Journal of Controlled Release, volumen 130, número 1, páginas 29-37; 2008; ISSN 1873-4995. * |
Also Published As
Publication number | Publication date |
---|---|
ES2422657B1 (es) | 2014-06-11 |
WO2013117793A1 (es) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX369121B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
MX348823B (es) | Formulaciones estables de linaclotida. | |
PH12015501096A1 (en) | Composition for immediate and extended release | |
MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
TN2012000488A1 (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
WO2014137797A3 (en) | Stable glucokinase activator compositions | |
WO2014033526A9 (en) | Pharmaceutical compositions of etoricoxib | |
WO2014016754A3 (en) | Pharmaceutical compositions of proton pump inhibitor | |
MX2015005762A (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
MX364652B (es) | Formulacion farmaceutica que comprende ciclesonida. | |
WO2010079433A3 (en) | Pharmaceutical composition comprising melogliptin | |
UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
MX2015015681A (es) | Composicion farmaceutica que comprende fingolimod. | |
ES2422657A1 (es) | Composición farmacéutica sólida de cilostazol | |
WO2013054178A3 (en) | Extended release pharmaceutical compositions containing carmabazepine | |
WO2013168179A3 (en) | Controlled release pharmaceutical formulations of antiviral agents | |
EA201491477A1 (ru) | Фармацевтические составы, содержащие флупиртин | |
IN2013MU01226A (es) | ||
IN2013MU03656A (es) | ||
MX2012014969A (es) | Composiciones farmaceuticas estables de amlodipina con telmisartan. | |
WO2011107922A3 (en) | Extended release composition of milnacipran | |
MX2013004248A (es) | Composiciones farmaceuticas topicas que comprenden etodolaco. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 2422657 Country of ref document: ES Kind code of ref document: B1 Effective date: 20140611 |